Puerarin concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production in human osteoblastic MG-63 cells

Puerarin decreases bone loss and collagen destruction in rats with ligature‐induced periodontitis

“…Wang et al . showed that puerarin stimulated OPG and inhibited RANKL production by human osteoblasts. This result is different from that of the present study, in which puerarin inhibited RANKL expression, but did not increase the OPG level.…”

“…This phenomenon may be attributed to the more varied cell types and complicated in vivo microenvironment in the present study compared with the previous in vitro study. However, the RANKL/OPG ratio, which is considered the critical determinant in the regulation of osteoclast activity and bone resorption , and the number of active osteoclasts were reduced by puerarin, thereby reducing alveolar bone loss.…”

Puerarin, isolated from Pueraria lobata (Willd.), protects against diabetic nephropathy by attenuating oxidative stress

“…In addition, PR has been promoted as a therapy for DN by reducing serum levels of TNF-α and IL-6 (Wang et al, 2014). Meanwhile, our previous study found that PR functioned as anti-diabetic activity through elevating insulin expression and maintaining metabolic homoeostasis in STZ-induced diabetic mice (Wu et al, 2013).…”

Puerarin Prevents LPS-Induced Osteoclast Formation and Bone Loss <i>via</i> Inhibition of Akt Activation

“…Puerarin, a natural isoflavones from Pueraria lobata OHWI (Wild) root, has been widely used in the prevention and treatment of hypertension, coronary artery heart disease, cerebral infarction and diabetes. Some preclinical in vivo and in vitro studies reported that puerarin was able to enhance new bone formation, [22][23][24] and prevent bone loss through an estrogen-like effect. 10,25,26) Consistent with their results, puerarin inhibited LPS-induced TRAP(+) MNCs formation in a dosedependent manner (Fig.…”